| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Madrigal Pharmaceuticals, Inc. (MDGL) has 11 insiders with recent SEC Form 4 filings, including 0 buys and 84 sells. MDGL is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 452.2K | $228.71M | - | |
| Dir | 199.7K | $100.98M | - | |
| Dir | 199.7K | $100.98M | - | |
| CEO | 150.1K | $75.90M | - | |
| Dir | 27.3K | $13.83M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 14, 2024 | Waltermire Robert E.48 | Senior VP, Chief Pharma Dev. | Sale+OE | 1,900 | $280.00 | $532,000.00 | -25.7% | -15.4% | +6.5% | |
| Jun 12, 2024 | Waltermire Robert E.48 | Senior VP, Chief Pharma Dev. | Sale+OE | 2,000 | $285.00 | $570,000.00 | -26.7% | -17.5% | +4.0% | |
| May 21, 2024 | Waltermire Robert E.48 | Senior VP, Chief Pharma Dev. | Sell | 1,036 | $231.34 | $239,668.24 | -15.9% | +5.9% | +14.3% | |
| May 14, 2024 | Craves Fred B | Director | Sale+OE | 22,489 | $212.88 | $4,787,404.04 | -0.5% | +14.7% | +34.1% | |
| Apr 8, 2024 | Friedman Paul A | Director | Sale+OE | 26,270 | $246.19 | $6,467,490.86 | -1.9% | +16.9% | +21.8% | |
| Apr 8, 2024 | Taub Rebecca | Pres., R&D, And CMO | Sale+OE | 2,676 | $245.99 | $658,257.61 | - | +16.9% | +21.8% | |
| Apr 5, 2024 | Taub Rebecca | Pres., R&D, And CMO | Sale+OE | 73,888 | $243.92 | $18,022,588.47 | -0.8% | +13.8% | +29.4% | |
| Apr 5, 2024 | Friedman Paul A | Director | Sale+OE | 73,730 | $243.93 | $17,984,804.49 | -1.9% | +13.8% | +29.4% | |
| Apr 2, 2024 | Daly James M | Director | Sale+OE | 24,555 | $251.65 | $6,179,149.02 | -34.1% | +14.2% | +36.9% | |
| Apr 2, 2024 | Bate Kenneth | Director | Sale+OE | 11,212 | $244.49 | $2,741,218.93 | -33.1% | +14.2% | +36.9% |